MedCity News
OCTOBER 30, 2022
We’ve been talking about improving patient satisfaction and creating a more patient-centric care experience for years. But we’ll never get there if we continue to be focused on transactional healthcare, which is where our efforts toward interoperability have traditionally been drawn.
pharmaphorum
OCTOBER 31, 2022
Verge Genomics has joined a select group of biotechs who have taken a drug discovered and developed using artificial intelligence into human testing. The small-molecule PIKfyve inhibitor – called VRG50635 – has been administered to the first subject in the phase 1 trial involving healthy volunteers, according to the San Francisco-based biotech, which was founded in 2015 by Alice Zhang and Jason Chen.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 31, 2022
After decades of setbacks, the respiratory syncytial virus (RSV) vaccine field has bounced back with positive Phase III trial results in older adults. There are currently five players in the race, with vaccines in Phase III of development from GlaxoSmithKline (GSK) , Pfizer , Johnson & Johnson , Moderna and Bavarian Nordic. However, recent data from GSK’s sub-unit vaccine, GSK-3844766A, have pushed the candidate to the top, with the highest efficacy demonstrated in a pivotal trial to date.
European Pharmaceutical Review
NOVEMBER 2, 2022
Researchers at Great Ormond Street Hospital for Children (GOSH) and University College London (UCL) Great Ormond Street Institute of Child Health (UCL GOS ICH) have used “universal” CRISPR-edited cells in humans for the first time to treat B-cell acute lymphoblastic leukaemia (B-ALL) child patients with engineered donor T cells. The treatment did not require matching donor cells, a major step in developing gene-edited cells for cancer treatment.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
NOVEMBER 1, 2022
Large employers, particularly self-insured companies, can demand a better and fairer system. They can use their contracting power to insist that their plans cover all FDA approved drugs.
pharmaphorum
NOVEMBER 2, 2022
Digital therapeutics are rapidly coming into the foreground to treat a variety of conditions. Ben Hargreaves discovers how chronic pain could be a key area for digital therapeutics, as they offer non-addictive and effective relief from the condition. The struggle to manage pain for individuals has been one that goes back a long way in history, with one of the earliest recorded medical prescriptions being for opium.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
European Pharmaceutical Review
OCTOBER 31, 2022
The race to the first-in-human (FIH) milestone is underscored by the rise in expedited programmes such as Fast Track designation, Accelerated Approval, Priority Review designation and Breakthrough Therapy designation. 1 Within these programmes, the ability to identify and solve challenges in the early stages with agility and flexibility is critical to successful early clinical trials that will help advance drugs from late stage through product launch.
MedCity News
OCTOBER 31, 2022
A transformation is underway in medical coding as automation permeates revenue cycle management, raising questions such as: How will automation affect how medical coders work? How advanced is coding automation currently? What kind of skill sets will be needed for these new types of coding?
pharmaphorum
OCTOBER 31, 2022
Actinium Pharma is on course to submit its targeted radiotherapy for acute myeloid leukaemia (AML) patients needing a bone marrow transplant in the US, buoyed by top-line data from a pivotal trial. The New York biotech said today that the SIERRA trial of Iomab-B – an antibody armed with a radioisotope designed to deliver targeted treatment to tumours and spare healthy tissues – met its primary objective.
PharmaTimes
NOVEMBER 4, 2022
Treatment will assist young people and children with symptoms of mild-to-moderate anxiety
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmaVoice
OCTOBER 31, 2022
How new tools are helping companies find and keep cancer patients in clinical studies.
MedCity News
NOVEMBER 4, 2022
Tech-enabled hospice provider Guaranteed recently closed a $6.5 million seed round, bringing its total funding to $9.25 million. Jessica McGlory founded the startup a year ago so that patients and their families can have more dignified and holistic end-of-life care experiences than what she and her father went through.
pharmaphorum
NOVEMBER 4, 2022
To address the supply chain vulnerabilities of the pharma industry, an innovative, collaborative blockchain-based system could help to keep track of drugs in transit and ensure they are stored in the correct conditions. The pace of technological advancement and focus in this area suggests that such a solution could be coming soon. While most supply chains were impacted by the Covid-19 pandemic, the demands it placed on pharmaceutical and medical supply chains were immense and underlined the impo
PharmaTimes
NOVEMBER 1, 2022
CamPROBE may save vital time and money while reducing the risk of infection
Pharmaceutical Technology
NOVEMBER 1, 2022
In a few weeks, the EU-funded research project Darwin EU will announce its first batch of data partners for the ambitious real-world data -driven Horizon 2020 project. This project centres around the use of electronic health records (EHRs) from different European countries to drive research and improve responses to expected and unexpected crises. A major objective of this project hinges on exploiting national EHR data to complete observational studies quicker than industry standards.
MedCity News
NOVEMBER 1, 2022
A patient affected by a data breach at Advocate Aurora Health has sued the healthcare […].
Medgadget
NOVEMBER 3, 2022
Medical Microinstruments , a medtech company with offices in Pisa, Italy and Delaware, USA, has developed the Symani Microsurgical Robot. The robotic system is designed to assist with microsurgical procedures, and it boasts a variety of advanced features to achieve this goal. These include a suite of the world’s smallest wristed surgical instruments, tremor reducing technology, and motion scaling (7-20X), to allow surgeons to perform very small and precise movements.
Healthcare Success
OCTOBER 31, 2022
Google Trends is a powerful but underutilized tool that helps healthcare marketers. Conduct search engine optimization (SEO) research, Identify current trends, Find out what people are interested in, And build better, more relevant campaigns. It also allows marketers to analyze search term popularity over time, explore related keywords, and compare how search terms vary across different geographical areas.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
NOVEMBER 3, 2022
Drug shortages continue affecting cardiovascular clinical practice across the world, reflecting rising demand and cost-effective manufacturing challenges. While the stock of currently affected drugs is expected to improve as production is increased in the near future, experts say it is likely that the cardiovascular sector will be particularly affected by such shortages in the long run as demand continues to grow from an aging population.
MedCity News
NOVEMBER 1, 2022
With the money, Daye is looking to reach more people with its products and services, whether that’s in the U.S., U.K. or Europe, Milanova said. The company will also expand research in gynecological health, focusing on conditions like endometriosis, PCOS and menopause. .
PharmaTimes
NOVEMBER 2, 2022
The study evaluated the safety, efficacy and immunogenicity of AELIX’s HIV vaccine
pharmaphorum
NOVEMBER 2, 2022
One of the highlights of Eli Lilly’s third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been described as “viral” take-up by the drugmaker. Lilly’s head of diabetes, Mike Mason, said on the company’s results call that the rollout of Mounjaro (tirzepatide) was “really unprecedented” for a new diabetes therapy in the US, and had been driven by “tremendous
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
European Pharmaceutical Review
NOVEMBER 4, 2022
A new computer model has successfully simulated a clinical trial evaluating the efficacy of aducanumab and donanemab for Alzheimer’s disease (AD), establishing a gradual increase in dosage up to the maximum dose helps to minimise cognitive decline and limit side effects. . The US-based researchers modelled personalised treatments for each virtual patient, assessing US Food and Drug Administration-approved aducanumab and donanemab, a therapy currently being evaluated and other potential AD
MedCity News
NOVEMBER 4, 2022
AstraZeneca already has a respiratory syncytial virus antibody drug on the market for premature babies. But the approval of Beyfortus, which was developed with Sanofi, covers all infants broadly and it protects during the entire RSV season with just a single shot.
PharmaTimes
OCTOBER 31, 2022
Information from 17 existing studies was reviewed, involving 91 million people
PharmaVoice
NOVEMBER 1, 2022
Leaders at Veeva believe the wording around decentralized trials has been exaggerated, and that a bigger-picture outlook is important as the pandemic winds down.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
European Pharmaceutical Review
NOVEMBER 1, 2022
Bristol Myers Squibb (BMS) has announced Reblozyl ® (luspatercept-aamt), the first erythroid maturation agent, showed improvement in red blood cell transfusion independence (RBC-TI) and haemoglobin (Hb) increase in severely anaemic adults with very low, low or intermediate-risk myelodysplastic syndromes (MDS). Reblozyl is a first-line therapy that promotes late-stage red blood cell maturation in animal models.
MedCity News
NOVEMBER 2, 2022
The 2023 Physician Fee Schedule conversion factor — which calculates how much a physician is reimbursed by Medicare for services — changed to $33.06, a $1.55 decrease from 2022 at $34.61. The American Medical Association strongly opposes the cuts.
Pharmaceutical Technology
OCTOBER 31, 2022
Hoffmann-La Roche (Roche Canada) has received approval from Health Canada for Actemra IV (tocilizumab for injection) vials to treat Covid-19 patients. The treatment is indicated for adult Covid-19 patients who are on systemic corticosteroids and need additional oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.
PharmaTech
NOVEMBER 2, 2022
Data analytics, modular equipment, digital tools, and risk-based validation improve speed, flexibility, and quality.
Expert insights. Personalized for you.
144 
Let's personalize your content